ICRA
-
Most hospitals expect double-digit revenue growth in FY2022: ICRA
During Q1 FY2022, the revenues and operating profit margin (OPM) for the ICRA sample set were at a multi-quarter high…
Read More » -
Hospitals may post 20-22 per cent revenue growth in FY2022: ICRA
Occupancies likely to improve to 61 – 63 per cent in FY2022, from 52.5 per cent in FY2021 The first…
Read More » -
Minimal impact of COVID-19 2.0 on the Indian pharma industry: ICRA
FY2022 growth estimated at 7-9 per cent The impact of COVID-19 on the Indian pharmaceutical companies was relatively limited in…
Read More » -
PLI scheme to help India become Aatmanirbhar in APIs: ICRA
Boost investments in high-value generics as well The production-linked incentive (PLI) schemes announced by the Government of India (GoI) for…
Read More » -
ECLGS 4.0 to support capacity creation in healthcare: ICRA
The proposed 100 per cent guarantee cover loans of up to Rs 2 crore for setting up oxygen generation plants…
Read More » -
RBI’s measure to infuse additional liquidity to boost healthcare infrastructure: ICRA
Loan tenor being capped at three years could impede availing the facility given that most industry players have a relatively…
Read More » -
Pre Budget 2021 expectation: Gaurav Jain, Vice President, ICRA
The pharmaceutical industry has shown resilience in the wake of the pandemic owing to the inelastic demand for drugs and…
Read More » -
Healthcare sector revenues likely to grow by a robust 20 per cent in FY2022: ICRA
Due to the high operating leverage, the EBITDA margin is likely to rise to ~13 per cent in FY2022 While…
Read More » -
Pharma sector revenue and margins likely to remain healthy in FY2022: ICRA
The credit metrics of leading pharma companies are expected to remain stable in view of future growth prospects in regulated…
Read More » -
ICRA Revises Outlook of Pharma Industry to Negative Following Coronavirus Outbreak
Mumbai: ICRA has revised its outlook on the Indian pharmaceutical industry from stable to negative in view of the ongoing…
Read More »